Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
143
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,320.41 | 7.47 | -0.09% |
| DAX 40 | 24,912.11 | 75.74 | -0.30% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,431.33 | 77.49 | 0.75% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,102.47 | 71.26 | 0.31% |
| Nikkei 225 | 57,699.09 | 1,335.15 | 2.37% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |